Stock listing
NASDAQ:AMLX Amylyx Pharmaceuticals, Inc. Stock
Home listing (NASDAQ) of Amylyx Pharmaceuticals, Inc.
Follow Amylyx Pharmaceuticals, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:AMLX
$28.86 USD +0.18 (+0.6%)
Close on Oct 30, 2026
- Day range
- $28.00 – $29.09 USDOct 30, 2026
- Volume
- 989,514 sharesOct 30, 2026
- Market cap
- $3.62B USDAt the close on Oct 30, 2026 · price × 125.5M shares outstanding
- 52-week range
- $10.83 – $41.14 USDLowest and highest trades, Oct 31, 2025 – Oct 30, 2026
- Traded on an average day
- $69.61M USDMedian day 1.44M shares · last 3 months, Jul 30, 2026 – Oct 30, 2026
Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:AMLX · Home | $28.86 USD | +0.18 (+0.6%) | 989,514 | $28.41 | $29.09 | $28.00 | $28.68 | Close on Oct 30, 2026 |
Daily closes
Last 3 months, Jul 30, 2026 – Oct 30, 2026 · NASDAQ:AMLX · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $28.86 | +0.18 | +0.6% | $28.41 | $29.09 | $28.00 | 989,514 | |
| $28.68 | +0.61 | +2.2% | $28.13 | $29.13 | $28.10 | 905,442 | |
| $28.07 | -0.23 | -0.8% | $28.11 | $28.48 | $27.58 | 1,064,464 | |
| $28.30 | +1.21 | +4.5% | $27.28 | $28.32 | $26.86 | 1,122,468 | |
| $27.09 | -0.11 | -0.4% | $27.25 | $27.98 | $26.23 | 1,371,103 | |
| $27.20 | -1.37 | -4.8% | $28.46 | $28.46 | $27.06 | 1,158,793 | |
| $28.57 | -0.46 | -1.6% | $28.84 | $30.00 | $28.51 | 1,307,959 | |
| $29.03 | +0.26 | +0.9% | $28.96 | $29.78 | $28.81 | 1,626,560 | |
| $28.77 | +1.44 | +5.3% | $27.54 | $29.23 | $27.15 | 1,613,173 | |
| $27.33 | +0.99 | +3.8% | $26.48 | $27.35 | $26.27 | 1,380,993 | |
| $26.34 | -1.31 | -4.7% | $27.65 | $27.65 | $26.20 | 1,150,596 | |
| $27.65 | +0.62 | +2.3% | $27.68 | $28.34 | $27.45 | 882,656 | |
| $27.03 | +0.18 | +0.7% | $26.80 | $27.77 | $26.46 | 1,166,178 | |
| $26.85 | -0.63 | -2.3% | $27.49 | $27.69 | $26.80 | 1,059,784 | |
| $27.48 | -0.66 | -2.3% | $28.04 | $28.49 | $27.40 | 1,106,108 | |
| $28.14 | +0.94 | +3.5% | $27.32 | $28.60 | $26.94 | 1,471,500 | |
| $27.20 | -0.23 | -0.8% | $27.01 | $27.53 | $26.04 | 2,622,162 | |
| $27.43 | -0.61 | -2.2% | $27.72 | $28.46 | $27.21 | 2,056,710 | |
| $28.04 | +0.26 | +0.9% | $27.97 | $28.50 | $27.00 | 1,279,463 | |
| $27.78 | -0.01 | 0.0% | $27.92 | $28.09 | $27.34 | 941,080 | |
| $27.79 | -0.29 | -1.0% | $28.50 | $28.81 | $27.64 | 912,394 | |
| $28.08 | -1.02 | -3.5% | $28.62 | $29.28 | $27.55 | 1,354,104 | |
| $29.10 | -0.18 | -0.6% | $29.47 | $29.62 | $28.64 | 1,307,046 | |
| $29.28 | -0.57 | -1.9% | $29.87 | $30.10 | $28.99 | 1,177,757 | |
| $29.85 | +0.36 | +1.2% | $29.10 | $30.14 | $28.71 | 1,020,546 | |
| $29.49 | -0.65 | -2.2% | $30.28 | $30.70 | $29.47 | 1,294,475 | |
| $30.14 | -0.465 | -1.5% | $30.73 | $31.00 | $29.83 | 1,420,508 | |
| $30.61 | -2.395 | -7.3% | $32.88 | $33.02 | $30.53 | 1,824,887 | |
| $33.00 | +0.61 | +1.9% | $32.52 | $33.19 | $32.25 | 1,383,682 | |
| $32.39 | -0.02 | -0.1% | $32.55 | $33.16 | $31.90 | 1,005,644 | |
| $32.41 | -1.53 | -4.5% | $34.21 | $34.21 | $32.25 | 2,048,794 | |
| $33.94 | +1.31 | +4.0% | $33.33 | $34.35 | $32.95 | 1,592,060 | |
| $32.63 | -0.52 | -1.6% | $33.05 | $33.75 | $32.10 | 1,366,183 | |
| $33.15 | -0.49 | -1.5% | $33.22 | $33.54 | $32.36 | 1,828,400 | |
| $33.64 | +2.02 | +6.4% | $31.84 | $33.96 | $31.57 | 1,925,353 | |
| $31.62 | -0.47 | -1.5% | $32.09 | $33.00 | $31.37 | 1,712,745 | |
| $32.09 | -0.31 | -1.0% | $31.81 | $32.57 | $31.44 | 1,777,482 | |
| $32.40 | -1.48 | -4.4% | $33.50 | $34.35 | $32.30 | 1,287,490 | |
| $33.88 | -0.22 | -0.6% | $33.49 | $34.72 | $33.10 | 1,166,534 | |
| $34.10 | +0.14 | +0.4% | $33.38 | $34.24 | $33.38 | 885,518 | |
| $33.96 | -0.53 | -1.5% | $34.49 | $35.31 | $33.73 | 1,556,792 | |
| $34.49 | +0.68 | +2.0% | $34.00 | $35.48 | $34.00 | 1,938,485 | |
| $33.81 | +0.06 | +0.2% | $33.49 | $34.21 | $32.99 | 1,821,535 | |
| $33.75 | -0.99 | -2.8% | $34.77 | $35.09 | $32.98 | 2,728,978 | |
| $34.74 | -2.44 | -6.6% | $36.78 | $37.68 | $34.48 | 1,361,802 | |
| $37.18 | +0.10 | +0.3% | $36.75 | $38.23 | $36.53 | 1,989,242 | |
| $37.08 | -0.38 | -1.0% | $37.13 | $37.69 | $35.79 | 2,815,491 | |
| $37.46 | -0.69 | -1.8% | $38.50 | $38.88 | $36.84 | 2,147,376 | |
| $38.15 | -0.51 | -1.3% | $38.64 | $39.38 | $37.45 | 3,714,467 | |
| $38.66 | -1.00 | -2.5% | $39.80 | $41.14 | $38.35 | 4,644,894 | |
| $39.66 | +1.06 | +2.7% | $37.49 | $40.44 | $37.37 | 8,540,882 | |
| $38.60 | +3.49 | +9.9% | $36.13 | $39.07 | $35.32 | 8,262,303 | |
| $35.11 | +13.68 | +63.8% | $29.91 | $35.39 | $28.00 | 23,980,270 | |
| $21.43 | -0.20 | -0.9% | $21.96 | $22.47 | $21.28 | 1,267,094 | |
| $21.63 | -0.85 | -3.8% | $22.35 | $22.39 | $21.29 | 1,588,794 | |
| $22.48 | -0.87 | -3.7% | $23.37 | $23.64 | $22.46 | 839,453 | |
| $23.35 | -0.28 | -1.2% | $23.86 | $24.08 | $23.30 | 1,454,262 | |
| $23.63 | +0.96 | +4.2% | $22.78 | $23.73 | $22.19 | 833,858 | |
| $22.67 | -0.15 | -0.7% | $22.68 | $23.03 | $22.00 | 1,331,114 | |
| $22.82 | -1.37 | -5.7% | $24.19 | $24.60 | $22.56 | 2,678,300 | |
| $24.19 | +2.34 | +10.7% | $21.10 | $24.36 | $21.10 | 3,537,969 | |
| $21.85 | -0.02 | -0.1% | $22.06 | $22.17 | $21.52 | 1,772,235 | |
| $21.87 | +1.70 | +8.4% | $20.34 | $22.28 | $20.32 | 3,426,238 | |
| $20.17 | -0.14 | -0.7% | $20.29 | $20.47 | $19.30 | 1,685,578 | |
| $20.31 | -0.44 | -2.1% | $20.74 | $20.87 | $19.30 | 1,832,489 | |
| $20.75 | +1.02 | +5.2% | $19.69 | $20.94 | $19.31 | 3,552,855 |
- Ticker
- NASDAQ:AMLX
- Asset type
- Stock
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Oct 6, 2026
Amylyx Pharmaceuticals to Present Topline Data from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual Meeting
Latest earnings call · Aug 6, 2026
Amylyx Pharmaceuticals (NASDAQ:AMLX) Q2 2026 Earnings Call
Replay and transcript
Latest deck · September 2026
Investor Presentation (September 2026)
Investor deck · 38 slides
Calls
Replays
Amylyx Pharmaceuticals (NASDAQ:AMLX) Q2 2026 Earnings Call
Thu, Aug 06, 2026 · 8:00 AM ET
Watch TranscriptAmylyx Pharmaceuticals (NASDAQ:AMLX) Q1 2026 Earnings Call
Thu, May 07, 2026 · 8:00 AM ET
Watch TranscriptAmylyx Pharmaceuticals (NASDAQ:AMLX) Q4 2025 Earnings Call
Tue, Mar 03, 2026 · 8:00 AM ET
Watch Transcript
Latest news
Amylyx Pharmaceuticals to Present Topline Data from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual Meeting
Oct 6, 2026
Closed $28.04 (+0.9%) on Oct 6, 2026
Amylyx Pharmaceuticals to Present at the Stifel 2026 Virtual Cardiometabolic Forum
Sep 23, 2026
Closed $30.61 (-7.3%) on Sep 23, 2026
Amylyx Pharmaceuticals to Present at the 24th Annual Morgan Stanley Global Healthcare Conference
Sep 8, 2026
Closed $33.88 (-0.6%) on Sep 8, 2026
Amylyx Pharmaceuticals Announces Pricing of an Upsized $500 Million Underwritten Public Offering of Common Stock
Aug 19, 2026
Closed $39.66 (+2.7%) on Aug 20, 2026
Amylyx Pharmaceuticals Announces $350.0 Million Proposed Public Offering of Common Stock
Aug 18, 2026
Closed $38.60 (+9.9%) on Aug 19, 2026
Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia
Aug 18, 2026
Closed $35.11 (+63.8%) on Aug 18, 2026
Amylyx Pharmaceuticals to Announce Topline Results from its Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia on August 18, 2026
Aug 17, 2026
Closed $35.11 (+63.8%) on Aug 18, 2026
Amylyx Pharmaceuticals Reports Second Quarter 2026 Financial Results
Aug 6, 2026
Closed $24.19 (+10.7%) on Aug 6, 2026
Amylyx Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026
Aug 3, 2026
Closed $20.17 (-0.7%) on Aug 3, 2026
Amylyx Pharmaceuticals to Present Data from First-in-Human, Dose-Ranging Phase 1 LUMINA Trial of AMX0114 in ALS at ENCALS 2026
Jun 23, 2026
Closed $16.37 (+0.6%) on Jun 23, 2026
Financings
Public offering of common stock
Aug 20, 2026
Made bigger: US$500.2M · US$35.5 a share · Leerink Partners +3
Dealers: Leerink Partners (co-lead), Morgan Stanley (co-lead), Guggenheim Securities (co-lead), LifeSci Capital (co-lead)
Use of proceeds: Pre-commercial activities for avexitide including manufacturing capacity, research and development, working capital and general corporate purposes
Decks
Investor Presentation (September 2026)
Investor deck · 38 slides · September 2026
Phase 3 LUCIDITY Trial of Avexitide in PBH Topline Data Conference Call (August 2026)
Conference · 17 slides · Aug 18, 2026
Investor Presentation (March 2026)
Investor deck · 41 slides · Mar 24, 2026
Q4 2025 Earnings Presentation
Earnings · 40 slides · Mar 3, 2026
Amylyx Pharmaceuticals, Inc. on 6ix
- News releases
- 23 in the last 12 months · 136 in all · newest Oct 6, 2026 · oldest 2022
- Calls
- 16 calls with a replay · 16 with a transcript · latest Aug 6, 2026
- Decks
- 11 decks · latest September 2026
Where Amylyx Pharmaceuticals, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:AMLX · Home listing · This page | NASDAQ | United States | USD |
| BOATS:AMLX | BOATS | United States | USD |
Log in to ask 6ix AI your own questions about Amylyx Pharmaceuticals, Inc.